INSULIN-SEMI-LONG SMC (injection suspension 100 units/ml)
Insulinum-semilongum SMC
International nonproprietary name (INN)
Insulin zinc suspension.
Pharmacotherapeutic group
Hormonal agent. Insulins.
Composition
1 ml of the suspension contains 100 units of multi component of pork insulin. Insulin Цsemi-long SMC is a drug based on MC (multi component) pork insulin of high degree of purification, containing NMT 10 ppm of proinsulin.
Pharmacological effect
Pharmacodynamics
Insulin-semi-long is of sugar decreasing action; it regulates carbohydrate metabolism, enhances glucose salvage and favors its transformation in glycogen.
The effect is revealed in 1-2 h. After injection; max.effect in 3-8 h., the duration is 10-16 h.
Pharmacokinetics
Absorption and initial effect depends on dose and volume of injection, concentration of insulin in a drug. Increased dose prolongs the effect. It is distributed irregularly between tissues. Diaplacental penetration of insulin is of no practical use due to rapid inactivation in placenta. It is mainly broken in liver (40-50% of the injected drug) and in kidneys (30% of the injected drug). Less than 1.5% of insulin is excreted unmodified.
Indications for usage
Insulin-semi-long SMC is administered for diabetes and diseases of insulin-therapy.
Administrationanddosage
Insulin-semi-long SMC is administered s.c. or i.m. INTREVENUS INJECTION OF INSULIN-SEMI-LONG SMC SUSPENSION IS PROHIBITED!
Shake gently the vial with suspension before usage to mix the content evenly.
Take insulin from the vial boring the rubber cap preliminary cleaned with alcohol or iodide solution, with sterile needle of the syringe. The temperature of insulin for injection is ambient, change the place of introduction.
Doses are determined individually subject to general state of the solution of the patient, degree of severity and characteristics of the disease and daily glucose level and glycemic profile.
Usual daily dose of insulin-semi-long SMC is 0.5 Ч 1 U/kg of the body weigh.
Special indications
¬ли¤ние на способность к вождению автотранспорта и управлению механизмами.
¬ св¤зи с первичным назначением инсулина, сменой его вида или при наличии значительных физических или психических стрессов, возможно снижение способности к вождению автомобил¤ или к управлению различными механизмами, а также зан¤ти¤м другими потенциально опасными видами де¤тельности, требующими повышенного внимани¤ и быстроты психических и двигательных реакций.
Adverse reaction
Conditioned carbohydrate metabolism: hypoglycemia. Allergicreactions: skineruption. Local reactions: lipodystrophy in place of injection (in long treatment). Other: transient vision disorder (usually at th beginning of therapy).
Contraindications
Hypoglycemia. Individual hypersensitivity to insulin or any of its components.
Safetymeasures
Administerthedrugwithcare. Overdose of the drug and undue intake of carbohydrates may cause hypoglycemia and hypoglycemic coma. Insulin may provoke allergic reaction of local and general nature. Administer this type of insulin if skin test is negative. In case of allergic reactions change insulin type and administer antiallergic therapy.
Follow safety measures in patients with coronary insufficiency or stroke, avoid overdoses.
Interaction with other drugs
Some drugs influence insulin demand.
Antihyperglycemic action of insulin-semi-long SMC is enhanced by inhibitors ћјќ, non-selective beta-adrenergic blockers, sulphanilamides, anabolitic steroids, tetraciclyne, clophibrat, cyclophosphamide, phenphluramin, ethanol-preparations. Antihyperglycemic action of the drug is decreased by oral contraceptives, glycocorticoids, thyroid hormones, thiazide(-type) diuretic, heparin, lithium preparations, tricyclic antidepressants. Under reserpin and salicylate drug effect either decreased or increased.
Overdose
Symptoms: hypoglycemia of various severity degree, hypoglycemic coma.
Treatment: in light hypoglycemia oral intake of glucose, in acute conditions i.v. stream injection (up to 50 ml of 40% solution) with concurrent introduction of glycagon or adrenaline.
Dosage form
Injection suspension 100 units/ml in vial 10 ml.
